CancerDrs

Head and Neck Cancer clinical trials in New Jersey

36 actively recruiting head and neck cancer trials at 31 sites across New Jersey.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Saint Barnabas Medical Center — Livingston, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in New Jersey:
  • Research Site — Camden, New Jersey
  • Research Site — East Brunswick, New Jersey
  • Research Site — Hackensack, New Jersey
  • Research Site — Summit, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in New Jersey:
  • Site 86 — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in New Jersey:
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in New Jersey:
  • Jersey City Medical Center — Jersey City, New Jersey
  • Saint Barnabas Medical Center — Livingston, New Jersey
  • Monmouth Medical Center — Long Branch, New Jersey
  • Morristown Medical Center — Morristown, New Jersey
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in New Jersey:
  • Local Institution - 2122 — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New Jersey:
  • Englewood Hospital and Medical Center (site 202) — Englewood, New Jersey
  • Summit Medical Group (site 205) — Florham Park, New Jersey
  • Atlantic Health System, Morristown Medical Center (site 124) — Morristown, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

ATATcH Alternating Treatment Plans for Advanced Cancer

The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced l…

Sponsor: Rutgers, The State University of New Jersey
NCT ID: NCT05358548
Sites in New Jersey:
  • Trinitas Hospital and Comprehensive Cancer Center — Elizabeth, New Jersey
  • Cancer Institute of New Jersey at Hamilton — Hamilton, New Jersey
  • RWJBarnabas Health - Jersey City — Jersey City, New Jersey
  • RWJBarnabas Health - Monmouth Medical Center Southern Campus — Lakewood, New Jersey
  • RWJBarnabas Health - Saint Barnabas Medical Center — Livingston, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New Jersey:
  • John Theurer Cancer Center — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06123338
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05307939
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited protocol activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with s…

Sponsor: Alentis Therapeutics AG
NCT ID: NCT06747585
Sites in New Jersey:
  • Hackensack University Medical Center — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma

This study will test whether limiting standard photon intensity modulated radiation therapy (IMRT) to exclude the oral tongue surgical site can decrease the risk of side effects caused by oral radiation. The researchers will also find out …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06485778
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

The purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment ap…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05544136
Sites in New Jersey:
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free …

Sponsor: Rutgers, The State University of New Jersey
NCT ID: NCT05332002
Sites in New Jersey:
  • RWJBarnabas Health - Robert Wood Johnson University Hospital — Hamilton, New Jersey
  • RWJBarnabas Health - Monmouth Medical Center Southern Campus — Lakewood, New Jersey
  • RWJBarnabas Health - Monmouth Medical Center — Long Branch, New Jersey
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
  • RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other canc…

Sponsor: Christian Hinrichs
NCT ID: NCT05686226
Sites in New Jersey:
  • Rutgers Cancer Institute — New Brunswick, New Jersey
  • RWJBarnabas Health - Robert Wood Johnson University Hospital — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. T…

Sponsor: Christian Hinrichs
NCT ID: NCT05639972
Sites in New Jersey:
  • Rutgers Cancer Institute — New Brunswick, New Jersey
  • RWJBarnabas Health - Robert Wood Johnson University Hospital — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)

The purpose of this study is to determine whether treatment of HPV-related oropharyngeal squamous cell carcinoma in patients with undetectable postoperative HPV circulating tumor DNA (cfHPVDNA) with transoral robotic surgery (TORS) alone c…

Sponsor: Icahn School of Medicine at Mount Sinai
NCT ID: NCT05419089
Sites in New Jersey:
  • Valley - Mount Sinai Comprehensive Cancer Care — Paramus, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

RAPA-201 Therapy of Solid Tumors

The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of monoclonal antib…

Sponsor: Rapa Therapeutics LLC
NCT ID: NCT05144698
Sites in New Jersey:
  • Hackensack University Medical Center — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in New Jersey:
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …

Sponsor: Pfizer
NCT ID: NCT05355701
Sites in New Jersey:
  • MSK Monmouth — Middletown, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.

Sponsor: AstraZeneca
NCT ID: NCT05877599
Sites in New Jersey:
  • Research Site — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05172245
Sites in New Jersey:
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
  • Rutgers New Jersey Medical School — Newark, New Jersey
View on ClinicalTrials.gov →

Showing 25 of 36 trials with sites in New Jersey. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25